Trinity Biotech (Trinity Biotech) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 26, 2024)

View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech 5-Year Yield-on-Cost %?

Trinity Biotech's yield on cost for the quarter that ended in Sep. 2023 was 0.00.

The historical rank and industry rank for Trinity Biotech's 5-Year Yield-on-Cost % or its related term are showing as below:

During the past 13 years, Trinity Biotech's highest Yield on Cost was 2.33. The lowest was 0.72. And the median was 1.19.

TRIB's 5-Year Yield-on-Cost % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 2.36
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Trinity Biotech's 5-Year Yield-on-Cost %

For the Diagnostics & Research subindustry, Trinity Biotech's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trinity Biotech's 5-Year Yield-on-Cost % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's 5-Year Yield-on-Cost % falls into.

Trinity Biotech 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Trinity Biotech is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Trinity Biotech (NAS:TRIB) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Trinity Biotech 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

TRBA:Germany

Address

IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8

Website

https://www.trinitybiotech.com

Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.